Intersecting roles CMS and FDA implications for pharmaceutical and device industries
|
|
- Dennis Day
- 5 years ago
- Views:
Transcription
1 Intersecting roles CMS and FDA implications for pharmaceutical and device industries Peter B. Bach, MD, MAPP Senior Adviser, Office of the Administrator Centers for Medicare & Medicaid Services
2 Traditional & intersecting roles CMS Traditional: pay for healthcare services Reality: Have to make decisions about what to pay for based on evidence Collects data on healthcare events by virtue of claims Has ability of spurring creation of new knowledge, through coverage FDA Traditional: ensure safety of medical items prior to market Reality: Sets evidentiary standards Ability to mandate post-market evidentiary development Great interest in post-market surveillance for adverse events
3 Examples of intersecting activities at CMS Coverage determinations Greater clarity in recent years Not redundant with FDA decisions But not unrelated Increasing work on coverage in the context of evidence development (CED) Drawing more attention to representativeness issues in clinical trials Surveillance Claims data for health outcomes assessment (not just cost calculations) Wennberg studies variations in costs without variations in outcomes Patterns of care studies underutilization of worthwhile therapy Observaitonal data analyses can estimate treatment effects Moving forward to create or motivate surveillance systems Registries for particular conditions Claims data, including drug claims for part D
4 Coverage static decisions Evidentiary standards increasingly codified Individual coverage determinations articulate reasoning Guidance documents articulate principles Standards not the same as FDA CMS sometimes non-covers drugs/devices despite labeling But, CMS often covers non-labeled uses Mandate: pay for items or services that are reasonable and necessary for management Evidence hierarchy topped by RCT s
5 Coverage dynamic decisions Coverage under evidence development Service/Item covered in the context of further evidence gathering Additional patient information gathered to assure appropriate use of item or service Can drive longitudinal data collection Specific investigation into impact of item or service on health being conducted as part of coverage (coverage only in a clinical trial)
6 Example of CED ICD (implantable cardiac defibrillator registry) Registry required as part of coverage Assures appropriate patients get service Longitudinal data on firing and mortality developed outside CMS Should produce valuable evidence about effectiveness and complications.
7 Another example of CED PET (positron emission tomography) scanning for cancer patients Coverage supported for all eligible patients Additional clinical data on patients required for coverage Collected through registry that is also addressing relevant clinical questions How does PET scan alter clinical mgmt
8 Another example of CED Coverage of oxygen therapy in NHLBI trial Will definitively answer whether it benefits patients with obstructive lung disease Can be used for future National Coverage Determination
9 Reasons CED gets triggered Reasonable questions need to be answered in order to make coverage determinations Patients studied not representative of Medicare population Further baseline data needed to assure appropriateness All move CMS coverage process from static to one of evidence development and surveillance
10 Surveillance Through paying based on fee-for-service, CMS gathers longitudinal health records for every beneficiary Decades of research evaluating these claims histories have demonstrated that patterns of claims can be analyzed to determine Patterns of care Impact of services
11 2 major surveillance initiatives CED through registries to establish monitoring systems (as for ICD s), prospective inception data developed with important clinical details beyond that available in claims Can overlap with FDA mandated post-market activities Use of claims for drugs and services to monitor for adverse events Fair amount of work looking at adverse events after major surgeries Some work looking at adverse events in relation to physician administered drugs (part B drugs) Next frontier is the Part D prescription drug system
12 Part D claims Surveillance systems should be large and comprehensive 1M p-years accumulated in FFS Medicare every 9 days 3M prescriptions filled daily Claims should capture impt events Medicare pays for care of most serious medical events and complications
13 Opportunities Evaluate individuals on various Part D drugs for frequency of healthcare events occurring in claims Adverse event surveillance Comparative studies between agents Assessment for rare but known side effects Evaluate adequacy of medications obtained by beneficiaries linked to diagnoses E.g. look for diabetics on and off ACEI s Evaluate impact of therapies in rarely studied populations Minorities, elderly
14 Cautions Adverse event monitoring will have to be conducted by analyzing millions of people on many millions of drugs experiencing many millions events Therefore, many many analyses will be performed any many different parts and combinations of data Epidemiologically, a risk that multiple analyses lead to false positive results How to handle this? Put systems in place to protect against false positives, like validation datasets
15 Conclusions CMS is doing a fair amount that is related to FDA s regulatory activity Clarifying evidentiary requirements drives study design during development phase Further enabling evidence development through CED enhances evidence base for particular uses and creates post-market surveillance resources Linking claims for drugs (part b and d) to other Medicare claims creates an enormous resource for adverse event monitoring.
Compensation and Reimbursement
492 Pharmacy Management: Compensation and Reimbursement Positions Compensation and Reimbursement Revenue Cycle Compliance and Management (1710) To encourage pharmacists to serve as leaders in the development
More information[Document Identifier: CMS-10377, CMS-10338, CMS-10465, CMS-10443, and CMS-10379]
This document is scheduled to be published in the Federal Register on 06/17/2016 and available online at http://federalregister.gov/a/2016-14405, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationClinical Trials Corporate Medical Policy
Clinical Trials Corporate Medical Policy File name: Clinical Trials File code: UM.GEN.02 Origination: 12/31/2013 Last Review: 03/2017 Next Review: 03/2018 Effective Date: 06/01/2017 Description This medical
More informationCoverage Analysis and Research Billing Beyond SOC vs. Study Paid. March 14, 2014
Coverage Analysis and Research Billing Beyond SOC vs. Study Paid March 14, 2014 Overview Laws and regulations for billing for patients in clinical trials CMS s National Coverage Decision, Affordable Care
More informationBackground to the Panel
IP21: Does Overseas Experience of Managed Entry Agreements Inform the New Japanese Pricing Scheme for Medical Devices? ISPOR Asia Pacific 2018 8-11 September 2018 Tokyo, Japan Background to the Panel Managed
More informationBlue Precision Silver HMO 106 Blue Precision HMO SM
Blue Precision Silver HMO 106 Blue Precision HMO SM OUTLINE OF COVERAGE 1. READ YOUR POLICY CAREFULLY. This outline of coverage provides a brief description of the important features of your Policy. This
More informationBUNDLED PAYMENTS IN RADIATION ONCOLOGY
BUNDLED PAYMENTS IN RADIATION ONCOLOGY CASE STUDIES IN INNOVATIVE SPECIALIST VALUE-BASED PAYMENT INITIATIVES: SPECIALTY PAYMENT REFORMS THAT REDUCE THE COSTS OF PROCEDURES Constantine Mantz MD Chief Medical
More informationBlue Precision Platinum HMO 004 OUTLINE OF COVERAGE
Blue Precision Platinum HMO 004 Blue Precision HMO SM Network OUTLINE OF COVERAGE 1. READ YOUR POLICY CAREFULLY. This outline of coverage provides a brief description of the important features of your
More informationCigna Administrative Policy
Cigna Administrative Policy Subject Clinical Trials Table of Contents Administrative Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/15/2014 Administrative
More informationChanges in some state or federal law or regulations or interpretations thereof may change the terms and conditions of coverage.
BlueCare Direct Silver SM 212 with Advocate BlueCare Direct SM OUTLINE OF COVERAGE 1. READ YOUR POLICY CAREFULLY. This outline of coverage provides a brief description of the important features of your
More informationSupplemental Special Advisory Bulletin: Independent Charity. Patients who cannot afford their cost-sharing obligations
Supplemental Special Advisory Bulletin: Independent Charity Patient Assistance Programs I. Introduction Patients who cannot afford their cost-sharing obligations for prescription drugs may be able to obtain
More informationOverview of Reimbursement Strategies for Novel Medical Technologies
Overview of Reimbursement Strategies for Novel Medical Technologies Nov 9, 2016 Goals and Objectives Develop understanding of U.S. medical technology reimbursement landscape and provide information about
More information2018 NMRHCA Benefits Presentation Presbyterian Senior Care (HMO-POS) Plan I and Plan II
2018 NMRHCA Benefits Presentation Presbyterian Senior Care (HMO-POS) Plan I and Plan II Who we are Started in 1908 as a Tuberculosis Sanatorium Presbyterian Today Locally owned, nonprofit healthcare system
More informationH.R. 6 21st Century Cures Act
CONGRESSIONAL BUDGET OFFICE COST ESTIMATE June 23, 2015 H.R. 6 21st Century Cures Act As ordered reported by the House Committee on Energy and Commerce on May 21, 2015 SUMMARY H.R. 6 would authorize appropriations
More informationTexas Vendor Drug Program. Drug Addition Process. Effective Date. December 2017
Texas Vendor Drug Program Drug Addition Process Effective Date December 2017 This is a working document to provide a resource to interested internal and external stakeholders. Questions or comments regarding
More informationEnhancing Medicare s ability to innovate
C h a p t e r1 Enhancing Medicare s ability to innovate C H A P T E R 1 Enhancing Medicare s ability to innovate Chapter summary In this chapter Current statutory provisions limit the flexibility of the
More informationTHE LINK BETWEEN FDA APPROVAL OF MEDICAL DEVICES AND REIMBURSEMENT
1 THE LINK BETWEEN FDA APPROVAL OF MEDICAL DEVICES AND REIMBURSEMENT Association of Corporate Counsel Legal Quick Hit September 6, 2011 Maria E. Gonzalez Knavel Partner Foley & Lardner LLP 414.297.5649
More informationProvide sufficient incentive for providers to maximize health outcomes and value while reducing costs;
March 27, 2017 Francis J. Crosson, MD Chair Medicare Payment Advisory Commission 425 I Street, N.W., Suite 701 Washington, DC 20001 By Electronic Delivery Dear Chairman Crosson: On behalf of the American
More informationA CONSUMER S GUIDE TO CANCER INSURANCE
A CONSUMER S GUIDE TO CANCER INSURANCE WHAT IS CANCER INSURANCE? Cancer insurance provides benefits only if you are diagnosed with cancer, as defined by the terms of the policy contract. These policies
More information2. Features of Medicare and Medicaid
1. Introduction The United States spends a sixth of its GDP to deliver health care to its citizens. Health care is provided through private physicians, pharmaceutical companies, private and public hospitals,
More informationChapter 8 Section 9.1
Other Services Chapter 8 Section 9.1 Issue Date: August 2002 Authority: 32 CFR 199.2(b), 32 CFR 199.4(b)(2)(vi), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(i), 32 CFR 199.5(d)(12); 32 CFR 199.17, and
More informationThe HPfHR 3-Tier System
The HPfHR 3-Tier System The basic level (Tier 1) of the new healthcare system would cover the entire population- from cradle to grave and would include, based on evidenced based data, all medical, surgical
More informationChapter 8 Section 9.1
Other Services Chapter 8 Section 9.1 Issue Date: August 2002 Authority: 32 CFR 199.2(b), 32 CFR 199.4(b)(2)(vi), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(i), 32 CFR 199.5(d)(12); 32 CFR 199.17, and
More informationInnovative Strategies for Managing the Rising Cost of Specialty Drugs
Innovative Strategies for Managing the Rising Cost of Specialty Drugs Mid-sized Retirement and Healthcare Plan Management Conference Chicago, IL June 5, 2013 Managing the Rising Cost of Specialty Drugs
More informationSuccessful disease management
Financial and Risk Considerations for Successful Disease Management Programs BY ARTHUR L. BALDWIN III, FSA, MAAA Milliman & Robertson, Seattle, Wash. ABSTRACT: Results for disease management [DM] programs
More informationExclusion of Orphan Drugs for Certain Covered Entities under 340B Program
Billing Code: 4165-15 DEPARTMENT OF HEALTH AND HUMAN SERVICES 42 CFR Part 10 RIN 0906- AA94 Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program AGENCY: Health Resources and Services
More informationWhat Regulatory Requirements are Responsible for the Transactions Standards?
Versions 5010 Why the Change? 99% of Medicare Part A and 96% of Part B Claims are submitted electronically New Accreditations standards adopted with Electronic Medical Records must align with the submitted
More informationRE: Comment on CMS-9937-P ( Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2017: Proposed Rule )
December 21, 2015 Centers for Medicare and Medicaid Services Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200 Independence Avenue, SW Washington, D.C. 20201 RE: Comment
More informationRESEARCH ENFORCEMENT Grant Fraud, Research Billing Irregularities and Other Scary Research Enforcement Issues
Kelly M. Willenberg, DBA, MBA, BSN, RN, CHRC, CHC Owner, Kelly Willenberg & Associates RESEARCH ENFORCEMENT Grant Fraud, Research Billing Irregularities and Other Scary Research Enforcement Issues 6TH
More information2017 NMRHCA Benefits Presentation
2017 NMRHCA Benefits Presentation Presbyterian Senior Care (HMO-POS) Plan I and Plan II _[code]_[mmddyyyy] Who we are Started in 1908 as a Tuberculosis Sanatorium Presbyterian Today Locally owned, nonprofit
More informationA Payor and Provider s Perspective on Drug Pricing. Sharon Levine, MD Executive Vice President, The Permanente Federation
A Payor and Provider s Perspective on Drug Pricing Sharon Levine, MD Executive Vice President, The Permanente Federation National Academies of Sciences, Engineering and Medicine Stakeholder Meeting on
More informationSeema Verma Administrator Centers for Medicare & Medicaid Services Attention CMS-9930-P P.O. Box 8016 Baltimore, MD RIN 0938-AT12
MARC MOSS, MD President POLLY E. PARSONS, MD President-Elect DAVID GOZAL, MD, MBA Immediate Past President JAMES M. BECK, MD Vice President JUAN C. CELEDON, MD, DrPH Secretary-Treasurer STEPHEN C. CRANE,
More informationPhRMA Perspective: Government Policies to Support Innovative Contracting Approaches
PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches CBI s PAP 2017 Michelle Drozd, Deputy Vice President Policy & Research Department October 12, 2016 Agenda Recent trends
More informationOne or More Sessions Policy
One or More Sessions Policy Policy Number 2017R0118B Annual Approval Date 7/12/2017 Approved By Reimbursement Policy Oversight Committee IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY You are responsible
More informationAvalere Health 2015 Industry Outlook
2015 Industry Outlook 2 Introduction Industry Outlook 2015 Changes in healthcare financing, delivery, and organization are transforming the sector. Health plans and providers are revising their business
More informationUnitedHealthcare Choice Plus. United HealthCare Insurance Company. Certificate of Coverage
UnitedHealthcare Choice Plus United HealthCare Insurance Company Certificate of Coverage For the Definity Health Savings Account (HSA) Plan 7PC of East Central College Enrolling Group Number: 711369 Effective
More informationDraft Chapter 9 Prescription Drug Benefit Manual
Draft Chapter 9 Prescription Drug Benefit Manual 423.504(b)(4)(vi), Prescription Drug Benefit Manual, Chapter 9, CMS guidance issued 1/11/2013...32. 9. Plan Sponsors' Prescription Drug Coverage Decisions.
More informationCANCER LEADERSHIP COUNCIL
CANCER LEADERSHIP COUNCIL A PATIENT-CENTERED FORUM OF NATIONAL ADVOCACY ORGANIZATIONS ADDRESSING PUBLIC POLICY ISSUES IN CANCER December 26, 2012 Via Electronic Filing http://www.regulations.gov The Honorable
More informationCHAPTER 8 Section 9.1, pages 1 through 7 Section 9.1, pages 1 through 7. CHAPTER 10 Section 7.1, pages 1 and 2 Section 7.
CHANGE 20 6010.60-M MAY 3, 2018 REMOVE PAGE(S) INSERT PAGE(S) CHAPTER 8 Section 9.1, pages 1 through 7 Section 9.1, pages 1 through 7 CHAPTER 10 Section 7.1, pages 1 and 2 Section 7.1, pages 1 and 2 2
More informationPost-Acute and Long-Term Care Reform / Estimating the Federal Budgetary Effects of the AHCA/NCAL/Alliance Proposal
Post-Acute and Long-Term Care Reform / Estimating the Federal Budgetary Effects of the AHCA/NCAL/Alliance Proposal April 2009 Prepared for: The American Health Care Association National Center for Assisted
More informationThe Medicare Advantage program: Status report
C H A P T E R12 The Medicare Advantage program: Status report C H A P T E R 12 The Medicare Advantage program: Status report Chapter summary In this chapter Each year the Commission provides a status
More informationDEADLINE WHERE TO SEND APPLICATIONS. Mail eight (8) copies of each completed application to the following address:
Centers for Medicare & Medicaid Services Center for Medicare Management 7500 Security Boulevard Baltimore, Maryland 21244-1850 Application for New Medical Services and Technologies Seeking to Qualify for
More informationinterchange Provider Important Message
Hospital Monthly Important Message Updated as of 09/13/2017 *all red text is new for 09/13/2017 The following documents were recently updated: CMAP Addendum B The date of the special cycle will be announced
More informationManufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis
Intersecting Worlds of Drug, Device, Biologics and Health Law AHLA/FDLI May 22, 2012 Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges by Andrew Ruskin Morgan Lewis The
More informationMedicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD) for Clinical Trials
DUHS Compliance Presentation Date: October 22, 2013 Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD) for Clinical Trials Presented by Colleen Shannon, DUHS Chief
More informationPharmacy Benefit Managers Overview
Pharmacy Benefit Managers Overview A Presentation to the House Health Innovation Subcommittee Mary Alice Nye, Ph.D. Health and Human Services Staff Director, OPPAGA December 6, 2017 Pharmacy Benefit Managers
More informationPartnership for Part D Access
Partnership for Part D Access www.partdpartnership.org EXECUTIVE SUMMARY A new study performed by Avalere Health, a leading strategic advisory company, and sponsored by the Partnership for Part D Access
More informationIn This Issue (click to jump):
May 7, 2014 In This Issue (click to jump): Analysis of Trends in Health Spending 2013 2014 Spotlight on Medicare Advantage Enrollment Oncology Drug Trend Report S&P Predicts Shift from Job-Based Coverage
More informationControlling Healthcare Costs through Innovative Methods - Analytics
Controlling Healthcare Costs through Innovative Methods - Analytics 2 What are we seeing? Trend is improving, but still significantly above general inflation 10% 8% 6% 9.0% 9.0% 8.5% 7.5% 6.5% 6.8% 6.2%
More informationI. PURPOSE. A. The primary objectives of Molina Healthcare s Transition Policy and Procedure are:
I. PURPOSE The purpose of the Policy and Procedure is to ensure necessary continuity of treatment and to provide adequate time and transition process to introduce the enrollee and their prescribing physician
More informationMarch 1, Dear Mr. Kouzoukas:
March 1, 2019 Mr. Demetrios L. Kouzoukas Principal Deputy Administrator and Director Center for Medicare Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Advance
More informationChapter 7 General Billing Rules
7 General Billing Rules Reviewed/Revised: 10/10/2017, 07/13/2017, 02/01/2017, 02/15/2016, 09/16/2015, 09/18/2014 General Information This chapter contains general information related to Health Choice Arizona
More informationMedicare Patient Access to Technology: The Lewin Group
Medicare Patient Access to Technology: The Lewin Group Medicare is playing an increasingly important role in determining whether America s seniors and disabled will have access to innovative medical technology,
More informationPredicting, and preventing costblooms. Nigam Shah, MBBS, PhD
Predicting, and preventing costblooms Nigam Shah, MBBS, PhD nigam@stanford.edu Healthcare in the United States What is the system for? Who are the key players, what are their roles, and what are their
More informationRecent data (lag time is less than 6 months)
Centricity 2 GE Centricity is an electronic health record system that enables ambulatory care physicians and clinical staff to document patient encounters and exchange clinical data with other providers
More informationMedicare Select Enrollment Application
Medicare Select Enrollment Application Underwritten by Unity Health Plans Insurance Corporation 840 Carolina Street Sauk City, WI 53583-1374 (800) 362-3309 Fax (608) 643-2564 QuartzBenefits.com Information
More informationAnnual Notice of Changes
Annual Notice of Changes January 1 December 31, 2018 Generations State of Oklahoma Group Retirees (HMO) GlobalHealth is an HMO plan with a Medicare contract. Enrollment in GlobalHealth depends on contract
More informationHOSPITAL OUTPATIENT BILLING AND REIMBURSEMENT GUIDE
FreedomBlue HOSPITAL OUTPATIENT BILLING AND REIMBURSEMENT GUIDE OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) FREEDOMBLUE (A Medicare Advantage PPO) Table of Contents Section I. Overview of APC Based Payment
More informationThe Fundamentals of Reimbursement
The Fundamentals of Reimbursement Understanding How Coverage, Coding, and Payment Impact a Medical Technology Kelli Hallas Executive Vice President of Reimbursement Emerson Consultants, Inc. OMTEC June
More informationHealth Care Reform: The Effect of the Affordable Care Act (ACA) and other Federal Mandates
Health Care Reform: The Effect of the Affordable Care Act (ACA) and other Federal Mandates (Only issues directly affecting the Trust Plan are addressed) Background On January 1, 2014, federally mandated
More informationKey Medicare Issues for Coverage and Reimbursement of Specialty Pharmaceuticals
Key Medicare Issues for Coverage and Reimbursement of Specialty Pharmaceuticals By Cindy Parks Thomas, Ph.D. A dvances in biotechnology have brought many effective new treatments for serious and debilitating
More informationExamining the patient journey: Case studies using linked health insurance claims and clinical data
Examining the patient journey: Case studies using linked health insurance claims and clinical data Daniel M. Huse, MA March 2017 White Paper The availability of electronic health data has virtually exploded
More information2019 Summary of Benefits Medicare Advantage Plans with Part D Prescription Drug Coverage
2019 Summary of Benefits Medicare Advantage Plans with Part D Prescription Drug Coverage H5434-023 H5434-024 January 1, 2019 December 31, 2019 The plan s service area includes:, Manatee, and Sarasota Counties
More informationAppendix I: Data Sources and Analyses. Appendix II: Pharmacy Benefit Management Tools
Appendix I: Data Sources and Analyses This brief includes findings from analyses of the Centers for Medicare & Medicaid Services (CMS) State Drug Utilization Data 1 and CMS 64 reports for federal fiscal
More informationAetna Select Clerical & Technical and Service & Maintenance Employees. Schedule of Benefits
Aetna Select Clerical & Technical and Service & Maintenance Employees Schedule of Benefits If this is an ERISA plan, you have certain rights under this plan. Please contact your employer for additional
More informationCareCore National Frequently Asked Questions (FAQ)
CareCore National Frequently Asked Questions (FAQ) 1. What is changing? Based on the implementation date of your provider notification letter, a limited range of Musculoskeletal Pain, Sleep and Cardiology
More informationADVANCE BENEFICIARY NOTICE OF NONCOVERAGE
ADVANCE BENEFICIARY NOTICE OF NONCOVERAGE Administrative Consultant Service, LLC CMS Guidelines for Advance Beneficiary Notice (ABN) June 1, 2012 Inside this issue: Revisions to ABN Guidelines Medical
More informationThe Changing Landscape of Medicare's Clinical Trial Coverage Policies for Medical Devices. Michael Sanchez, M.A., CCA Reimbursement Advisor
The Changing Landscape of Medicare's Clinical Trial Coverage Policies for Medical Devices Michael Sanchez, M.A., CCA Reimbursement Advisor Disclaimer The reimbursement information provided in this presentation
More informationDiscarded Drugs and Biologicals
Policy Number Discarded Drugs and Biologicals DDB01012011RP Approved By UnitedHealthcare Medicare Committee Current Approval Date 03/26/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is
More informationOffice of Compliance Services. Revenue Cycle and Billing Terminology and Definitions
Revenue Cycle and Billing Terminology and Definitions Advance Beneficiary Notice (ABN) Adjustment (aka write off ) Allowed amount Ancillary Service Appeal Authorization Centers for Medicare & Medicare
More information2019 Summary of Benefits Medicare Advantage Plans with Part D Prescription Drug Coverage
2019 Summary of Benefits Medicare Advantage Plans with Part D Prescription Drug Coverage H2758-002 H2758-008 January 1, 2019 December 31, 2019 The plan s service area includes: Manatee, Pinellas and Sarasota
More informationMCHO Informational Series
MCHO Informational Series Glossary of Health Insurance & Medical Terminology How to use this glossary This glossary has many commonly used terms, but isn t a full list. These glossary terms and definitions
More information2019 Summary of Benefits Medicare Advantage Plans with Part D Prescription Drug Coverage. BlueMedicare Choice (Regional PPO) R
2019 Summary of Benefits Medicare Advantage Plans with Part D Prescription Drug Coverage R3332-001 January 1, 2019 December 31, 2019 The plan s service area includes: 1 Y0011_92076_M 0818 CMS Accepted
More informationHighmark. APC Based Payment Methods
Highmark APC Based Payment Methods Provider Training Manual and Change Documentation Issued by: Provider Reimbursement Decision Support & Systems Implementation Table of Contents Section I. Overview of
More informationDecember 20, Submitted electronically via:
December 20, 2018 Submitted electronically via: http://regulations.gov/ Seema Verma Administrator Centers for Medicare & Medicaid Services U.S. Department of Health and Human Services Hubert H. Humphrey
More informationBuilding Clinical Trial Revenue Integrity Compliance Through Auditing and Understanding Payer Requirements
Building Clinical Trial Revenue Integrity Compliance Through Auditing and Understanding Payer Requirements Kelly Willenberg, DBA, RN, CHRC, CHC, CCRP Kelly Willenberg & Associates Wendy S. Portier, MSN,
More informationNew Options in Medicare Advantage: Addressing the Social Determinants of Health and More
New Options in Medicare Advantage: Addressing the Social Determinants of Health and More Over the last year, new laws, regulations, and guidance from the Centers for Medicare & Medicaid Services (CMS)
More informationMARCH VALUE OF OTC MEDICINES. to the U.S. Healthcare System
MARCH 2019 VALUE OF OTC MEDICINES to the U.S. Healthcare System TABLE OF CONTENTS SECTION 1 1 Executive Summary SECTION 2 3 Study Methodology SECTION 3 4 Study Findings SECTION 4 9 Sources SECTION 1 Executive
More informationAPPLICATION BY BLUECROSS BLUESHIELD OF WESTERN NEW YORK TO THE NEW YORK STATE DEPARTMENT OF FINANCIAL SERVICES FOR A PREMIUM ADJUSTMENT
1. Introduction. APPLICATION BY BLUECROSS BLUESHIELD OF WESTERN NEW YORK TO THE NEW YORK STATE DEPARTMENT OF FINANCIAL SERVICES FOR A PREMIUM ADJUSTMENT NAIC #: 55204 SERFF Tracking #: HLTH 129082986 TO
More informationThe 340B Drug Pricing Program
The 340B Drug Pricing Program Presentation at Alliance of Community Health Plans Medical Directors and Pharmacy Directors Meeting October 2012 Avalere Health LLC Avalere Health LLC The intersection of
More informationOHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy EMPAA 2017 October 30, 2017
OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy EMPAA 2017 October 30, 2017 Wedding Day Preparation The Big Moment is Here Mr. & Mrs. Anderson Today s Presentation Center
More informationA, B, C, Ds of Medicare
A, B, C, Ds of Medicare What you need to know for 2018 Introduction to Medicare Medicare provides an excellent foundation for the health care coverage of retirees, but the program is unlikely to meet all
More informationAge to Diagnosis Code & Procedure Code Policy
Age to Diagnosis Code & Procedure Code Policy Policy Number 2017R0086C Annual Approval Date 3/8/2017 Approved By Reimbursement Policy Oversight Committee You are responsible for submission of accurate
More informationPLAN B-1 PPO BENEFIT SUMMARY PLANTSMAN (MONTHLY)
PLANTSMAN (MONTHLY) All benefits are subject to eligibility, maximum Plan benefit, reasonable and customary determination (or negotiated fee amounts for PPO provider services), and any special limits noted
More informationStrategic Purchasing of Medical Devices
Strategic Purchasing of Medical Devices James C. Robinson Leonard D. Schaeffer Professor of Health Economics Director, Berkeley Center for Health Technology University of California, Berkeley Overview
More informationRISK SHARE AGREEMENTS
THIRD PLENARY: Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned Gergana Zlateva Pfizer Inc New York, NY, USA RISK SHARE AGREEMENTS Gergana Zlateva, PhD VP, Global Market Access
More informationMethodology to assess the cost impact of PMB benefit definitions
Methodology to assess the cost impact of PMB benefit definitions Version 1.0.0 07 March 2012 Contents 1 Background... 1 2 Aim... 1 3 Objectives... 1 4 Methods... 2 5 Variables for data collection, data
More informationReforming Beneficiary Cost Sharing to Improve Medicare Performance. Appendix 1: Data and Simulation Methods. Stephen Zuckerman, Ph.D.
Reforming Beneficiary Cost Sharing to Improve Medicare Performance Appendix 1: Data and Simulation Methods Stephen Zuckerman, Ph.D. * Baoping Shang, Ph.D. ** Timothy Waidmann, Ph.D. *** Fall 2010 * Senior
More informationMedicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount? 1 Executive Summary The Medicare Part B program reimburses providers for physician-administered (via infusion
More informationBRONZE PPO PLAN BENEFIT SUMMARY
BRONZE PPO PLAN BENEFIT SUMMARY All benefits are subject to eligibility, maximum Plan benefit, reasonable and customary determination (or negotiated fee amounts for PPO provider services), and any special
More informationOHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy National Conference of State Legislators San Diego, CA December 10,
OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy National Conference of State Legislators San Diego, CA December 10, 2017 Today s Presentation Center for Evidence-based Policy
More informationHealth Law 101: Issue-Spotting In Dealing With Health-Care Providers. by William H. Hall Jr.
Health Law 101: Issue-Spotting In Dealing With Health-Care Providers by William H. Hall Jr. The anti-kickback statute prohibits arrangements that might be common in other industries. Health care is among
More informationChapter 9 Medicaid and 340B
Chapter 9 Medicaid and 340B A. Introduction UPDATED 1. The complex intersection of Medicaid and 340B The intersection of 340B and Medicaid is one of the most complex and significant areas within any health
More informationSUMMARY OF BENEFITS $500 ** Effective from January 1, 2016 through December 31, 2016 Insured by Cigna Health and Life Insurance Company
For Retirees of Colby College Your Cigna Medicare Surround Plan Effective from January 1, 2016 through December 31, 2016 Insured by Cigna Health and Life Insurance Company INTRODUCTION TO YOUR CIGNA MEDICARE
More informationBlue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - Pharmacy
Blue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - In this Section there are references unique to Blue Essentials, Blue Advantage HMO and Blue Premier. These network specific
More informationDO YOU SPEAK MEDICARE PART D?
CMA WEEKLY ALERT JULY 21, 2005 DO YOU SPEAK MEDICARE PART D? In the next few months the older people and people with disabilities who rely on Medicare, along with their families, friends, and advocates,
More informationHOSPITAL OUTPATIENT BILLING AND REIMBURSEMENT GUIDE
HOSPITAL OUTPATIENT BILLING AND REIMBURSEMENT GUIDE OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS) FREEDOM BLUE (A Medicare Advantage PPO) PROVIDER TRAINING MANUAL AND CHANGE DOCUMENTATION Table of Contents
More informationHealth Insurance (Chapters 15 and 16) Part-2
(Chapters 15 and 16) Part-2 Public Spending on Health Care Public share of total health spending over time in the U.S. The Health Care System in the U.S. Two major items in public spending on health care:
More informationCoverage and Billing Issues for Clinical Research
Coverage and Billing Issues for Clinical Research John E. Steiner, Jr., Esq Chief Compliance Officer Cleveland Clinic Health System Cleveland, Ohio The Second Annual Medical Research Summit Washington,
More informationChapter 1: A Distinctive System of Health Care Delivery
Multiple Choice Questions Delivering Health Care in America, Sixth Edition Chapter 1: A Distinctive System of Health Care Delivery 1. The primary objectives of a healthcare system include all of the following
More information